Anavex Life Sciences (AVXL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Soumit Roy from JonesTrading maintained a Buy rating on the stock and has a $15.00 price target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Soumit Roy has given his Buy rating due to a combination of factors surrounding Anavex Life Sciences. One of the primary reasons is the anticipated feedback from the European Medicines Agency (EMA) regarding the approval of blarcamesine for Alzheimer’s disease. The company has indicated that they expect to receive this feedback by the end of 2025 or early 2026, which could significantly impact the stock’s performance if positive.
Additionally, Anavex is actively exploring partnership options and has already manufactured a substantial inventory of blarcamesine, indicating readiness for potential market entry. Although there is uncertainty regarding U.S. approval and no concrete partnership deals have been announced, the ongoing discussions with the FDA and the completion of a Phase 2 trial for ANAVEX3-71 in schizophrenia demonstrate the company’s progress in its pipeline. These factors collectively contribute to the optimistic outlook and the Buy rating.
In another report released on May 14, H.C. Wainwright also reiterated a Buy rating on the stock with a $42.00 price target.